GlassScriptPhysician profile
Terry M Lee
NPI 1184796104
$19,273.25
in general payments reported to CMS, 2019-2025
50 companies · $2,519 in 2025
The $2,519 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,303 · 2020: $2,538 · 2021: $3,822 · 2022: $3,253 · 2023: $2,211 · 2024: $1,628 · 2025: $2,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,295 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,294.51 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,125.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,908.00 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $1,463.58 | 2019-2022 | |
| Amgen INC. | $1,195.42 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $955.03 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $923.66 | 2019-2023 | |
| Lilly USA, LLC | $782.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $755.57 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $751.01 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $597.11 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $574.74 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $521.78 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $478.01 | 2019-2022 | |
| Abbott Laboratories | $457.79 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Radius Health, INC. | $430.69 | 2019-2024 | Tymlos |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.